News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Data to be presented at the 2019 Genitourinary Cancers Symposium
Jan 10, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
- Photos 4
Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Dec 14, 2018

Astellas Acquires Potenza Therapeutics

Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline
- Photos 1
Dec 12, 2018

Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing
- Photos 1
Dec 10, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Dec 3, 2018

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Nov 28, 2018

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -
Nov 20, 2018

Astellas Global Health Foundation Launches - Foundation to Support Improving Access to Health for Underserved Populations -
Nov 20, 2018

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+

Show per page